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Chromosomal instability is a common finding in all
malignant tumor types. Structural chromosome aberra-
tions are frequently caused by non-random DNA
damage at locus-specific regions of the genome, known
as common fragile sites (cFS). DNA at cFS can suffer
double-strand breaks when cells are grown under condi-
tions of replication stress. cFS are considered to be
present in all individuals and represent a normal com-
ponent of chromosomal structure. The human genome
contains approximately 120 cFS regions that have been
cytogenetically mapped to specific sites distributed over
all chromosomes. Instability at cFS thought to be a criti-
cal initiating event in the generation of genomic DNA
damage during tumor development. One prototypic
example for the role of cFS activation is oncogene
amplification, where multiple breakage-fusion-bridge
cycles (BFB cycles) depart from an activated cFS with
the consequence of increased gene copy numbers, like
for instance the amplified MYCN gene in the pediatric
cancer neuroblastoma.
We have initiated a project known by the acronym
FRAGILOME, which is positioned within the Human
Cancer Genome endeavour and has its major goal in (i)
mapping and identifiying of the full repertoire of cFS
genes in the human genome, (ii) determining the genetic
material damaged upon activation and unfaithful repair
of cFS, and (iii) defining t h er o l et h a tc F Sg e n e sm a y
have in human tumorigenesis [1,2].
Mapping and identifying cFS genes is being done by
multicolor chromosomal fluorescence in situ hybridisa-
tion (FISH). Determining the genetic material damaged
as the result of cFS activation is done by a designer high
density CGH array (FRA-CGH chip) targeting sequences
of identified cFS genes.
The preferential cFS activation at early stages of carci-
nogenesis makes these genomic regions likely targets for
identifying critical alterations of genetic material in
human cancers and for discovering new DNA biomar-
kers for clinical use.
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